Table 2 Analysis of the associations between clinicopathological factors and 4R node metastasis (n = 393)

Sex

0.922

 Male

311

16 (5.1)

295 (94.9)

 Female

82

4 (4.9)

78 (95.1)

Age (years)

0.736

  ≤ 65

323

17 (5.3)

306 (94.7)

  > 65

70

3 (4.3)

67 (95.7)

Tumor location

0.408

 Upper

58

3 (5.2)

55 (94.8)

 Middle

278

16 (5.8)

262 (94.2)

 Lower

57

1 (1.8)

56 (98.2)

Histological grade

0.057

 G1

63

0 (0.0)

63 (100)

 G2

218

12 (5.5)

206 (94.5)

 G3

112

8 (7.1)

104 (92.9)

pT stage

0.317

 T1a-T1b

42

0 (0.0)

42 (100)

 T2

66

3 (4.5)

63 (95.5)

 T3

274

16 (5.8)

258 (94.2)

 T4

11

1 (9.1)

10 (90.9)

pN stage

 < 0.001

 N0

188

0 (0.0)

188 (100)

 N1

106

4 (3.8)

102 (96.2)

 N2

66

6 (9.1)

60 (90.9)

 N3

33

10 (30.3)

23 (69.7)

pTNM stage

 < 0.001

 0

1

0 (0.0)

1 (100.0)

 Ia

1

0 (0.0)

1 (100.0)

 Ib

36

0 (0.0)

36 (100.0)

 IIa

53

0 (0.0)

53 (100.0)

 IIb

103

0 (0.0)

103 (100.0)

 IIIa

18

0 (0.0)

18 (100.0)

 IIIb

146

10 (6.8)

136 (93.2)

 IVa

35

10 (28.6)

25 (71.4)

Tumor length (mm)

0.653

  ≤ 35

195

11 (5.6)

184 (94.4)

  > 35

198

9 (4.5)

189 (95.5)

 2R metastasis

85

11 (12.9)

74 (87.1)

 < 0.001

 2L + 4L metastasis

39

4 (10.3)

35 (89.7)

0.099

 8U metastasis

30

3 (10.0)

27 (90.0)

0.376